| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/01/2008 | US7350331 Method for producing metabolites from plants cultivated in soil-less medium |
| 04/01/2008 | CA2530543C Illudin analogs as anti-tumor agents |
| 04/01/2008 | CA2414320C Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections |
| 04/01/2008 | CA2371896C Method of increasing the content of flavonoids and phenolic substances in plants |
| 04/01/2008 | CA2339004C Antioxidant composition and method of treating diseases using same |
| 04/01/2008 | CA2149408C Compositions for curing affected abnormal tissues, method for the preparation thereof, and usage thereof |
| 03/27/2008 | WO2008036981A1 Methods for treating mica-related disorders |
| 03/27/2008 | WO2008036954A1 Use of n- [5- [ [ [5- (1, 1-dimethylethyl) -2-oxazoyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide |
| 03/27/2008 | WO2008036792A2 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors |
| 03/27/2008 | WO2008036653A2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 03/27/2008 | WO2008036642A2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 03/27/2008 | WO2008036565A1 Tripeptides for treating cancer metastasis, prostate cancer and melanoma |
| 03/27/2008 | WO2008036277A1 Pyraz0l0(l,5-a) (1, 3, 5) triazine and pyrazolo (1, 5-a) pyrimidine derivatives useful as protein kinase inhibitors |
| 03/27/2008 | WO2008036272A1 HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF |
| 03/27/2008 | WO2008036271A1 Formulations for therapeutic administration of thyroid stimulating hormone (tsh) |
| 03/27/2008 | WO2008036046A1 IMIDAZO[l,2-a]PYRIDINE HYDROXYMATE COMPOUNDS THAT ARE INHIBITORS OF HISTONE DEACETYLASE |
| 03/27/2008 | WO2008036022A1 Tetrahydro-lh-pyrido[3,4-b] indole derivatives as cb1 receptor ligands |
| 03/27/2008 | WO2008036021A1 Tetrahydro-lh-pyrido [3,4 -b] indole derivatives as cbl receptor ligands |
| 03/27/2008 | WO2008035823A1 Cell death inhibitor |
| 03/27/2008 | WO2008035757A1 Jelly-like food containing ubiquinol |
| 03/27/2008 | WO2008035756A1 Anti-angiogenic composition comprising extract having anti-angiogenic activity and lecithin |
| 03/27/2008 | WO2008035692A1 Cancer cell identification marker and cancer cell proliferation inhibitor |
| 03/27/2008 | WO2008035629A1 Pyrazolopyrimidine derivative |
| 03/27/2008 | WO2008035461A1 Postoperative adjuvant chemotherapy for gastric cancer |
| 03/27/2008 | WO2008035350A1 Antigen specific multi epitope vaccines |
| 03/27/2008 | WO2008035239A1 Phenyl derivatives and their use as immunomodulators |
| 03/27/2008 | WO2008035209A2 Quinoline and quinazoline derivatives as inhibitors of protein tyrosine kinase activity |
| 03/27/2008 | WO2008035208A2 The use of polymethoxyflavones for the non apoptotic inhibition of cancer cell growth |
| 03/27/2008 | WO2008035024A1 Ccn3 peptide |
| 03/27/2008 | WO2008034974A1 2-ARYL-6-PHENYLIMIDAZO[1,2-α]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF |
| 03/27/2008 | WO2008034920A1 Method for extracting substances with antineoplasic activity from the ceropegia fusca plant, and pharmaceutical compositions containing them |
| 03/27/2008 | WO2008034910A1 Treatment of pain using satraplatin |
| 03/27/2008 | WO2008034776A1 Method for treating cancer harboring egfr mutations |
| 03/27/2008 | WO2008034644A2 Process for making anastrozole |
| 03/27/2008 | WO2008034579A1 2-heterocyclyl-5-phenoxymethylpyridine derivatives as anticancer agents |
| 03/27/2008 | WO2008034346A1 Composition and method for treating tumor |
| 03/27/2008 | WO2008034181A1 ANTI-CANCER ANTIBODIES AGAINST LEWISy AND LEWISb ANTIGENS |
| 03/27/2008 | WO2008006895A3 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators |
| 03/27/2008 | WO2008006511A3 Use of fosfluridine tidoxil (ft) for the treatment of intraepithelial proliferative diseases |
| 03/27/2008 | WO2008005621A3 Compositions and methods for modulating immune responses |
| 03/27/2008 | WO2008000070B1 Glycyrrhetinic acid derivatives |
| 03/27/2008 | WO2007147497A3 Use of a disintegrin-like and metalloproteinase with thrombospondin type 1 motif (adamts1) as a therapeutic or diagnostic target |
| 03/27/2008 | WO2007143096A3 Compounds for treating cancers |
| 03/27/2008 | WO2007135538A3 Reversion of malignant phenotype with 9-hydroxy ellipticine derivatives |
| 03/27/2008 | WO2007135026A3 Substituted pteridines as therapeutic agents |
| 03/27/2008 | WO2007134876A3 HIGH AFFINITY HUMAN AND HUMANIZED ANTI-α5β1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY |
| 03/27/2008 | WO2007115837B1 Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule |
| 03/27/2008 | WO2007105015A3 DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID |
| 03/27/2008 | WO2007092939A3 Antigenic gm-csf peptides and antibodies to gm-csf |
| 03/27/2008 | WO2007080114A3 Macromolecule conjugate |
| 03/27/2008 | WO2007071958A3 Combination of zd6474 and pemetrexed |
| 03/27/2008 | WO2007071363A3 METHODS OF USING THE CALCINEURIN A VARIANT Cnaβ1 |
| 03/27/2008 | WO2007056435A3 Dynamin mediated diseases and associated methods and products |
| 03/27/2008 | WO2007036717A8 4- (4-BROMO-2-FLUOROANILINO) -6-METHOXY-7- (l-METHYLPIPERIDIN-4 -YLMETHOXY) QUINAZOLINE MONOHYDRATE |
| 03/27/2008 | US20080077372 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 03/27/2008 | US20080076813 Benzene, Pyridine, and Pyridazine Derivatives |
| 03/27/2008 | US20080076800 Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide |
| 03/27/2008 | US20080076795 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators |
| 03/27/2008 | US20080076792 Heterobifunctional Polymeric Bioconjugates |
| 03/27/2008 | US20080076791 5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin and its preparation and use for the treatment of cancer |
| 03/27/2008 | US20080076790 Anticancer agents; 5(R)-(2''-hydroxyethoxy)-20(S)-camptothecin; X-ray powder diffraction |
| 03/27/2008 | US20080076780 For treatment of cancer; kits |
| 03/27/2008 | US20080076778 PARP (poly-ADP ribose polymerase); drug screening; computer networks |
| 03/27/2008 | US20080076775 3-(2-alkoxycarbonyl-3-indolyl)-3-oxo-propionic acid ester or propionamide intermediates: methyl 3-[6-fluoro-2-(methoxycarbonyl)-1-methyl-1H-indol-3-yl]-3-oxopropanoate; peripheral neuropathy, Parkinson's disease, Alzheimer's disease |
| 03/27/2008 | US20080076768 Pharmaceutical compounds |
| 03/27/2008 | US20080076767 Controlling cell proliferation, cell differentiation,autoimmune disease; N-[4-(3-amino-1,2-benzisoxazol-4-yl)phenyl]-N'-(3-methylphenyl)urea; 2-[4-(3-amino-1H-indazol-4-yl)phenyl]-N-(3-chlorophenyl)acetamide; N-[4-(3-amino-1,2-benzisothiazol-4-yl)phenyl]-N'-(3,5-dimethylphenyl)urea; anticarcinogenic |
| 03/27/2008 | US20080076763 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(2S)-2-morpholinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol for treating cancer and arthritis |
| 03/27/2008 | US20080076758 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors |
| 03/27/2008 | US20080076718 oligopeptide or polypeptide amino acid sequences as biodrug antitumor agents, anticarcinogenic agents; treating autoimmune diseases, AIDS, inflammatory diseases, cardiovascular disorder of ischemic processes, allograft rejection, cerebral strokes, traumas, burns, Alzheimer's disease, Parkinson's disease |
| 03/27/2008 | US20080076703 Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium |
| 03/27/2008 | US20080076173 Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| 03/27/2008 | US20080076172 Vectors for tissue-specific replication |
| 03/27/2008 | US20080076148 Using presence hyaluronic acid on surface of cell as evaluative tool in screening for preferential progenitor cells |
| 03/27/2008 | US20080076146 Harvesting, separating, culturing and exposing tissue to antiproliferative agents, monitoring variation in tissue propagation; immunotherapeutics; wound healing agents |
| 03/27/2008 | US20080075769 Psychostimulant containing pharmaceutical composition |
| 03/27/2008 | US20080075762 Compositions for delivery of drug combinations |
| 03/27/2008 | US20080075744 Pharmaceutical composition for cancer treatment containing cells that express a membrane cytokine |
| 03/27/2008 | US20080075742 synergistic biomedical activity as immunostimulants; biodrugs for prevention and/or treatment of cancer, treatment of allergic conditions, malignancies, chronic infections, autoimmune phenomena and age-related imbalances; adverse side effects of irradiation |
| 03/27/2008 | US20080075739 Attenuated Salmonella SP12 Mutants as Antigen Carriers |
| 03/27/2008 | US20080075734 Genetic Immunization |
| 03/27/2008 | US20080075729 ras-mediated; administering immunosuppressive for immune constituents that may interfere with the systemic delivery of the reovirus; antiproliferative; in the neoplastic cells phosphorylation of PKR is prevented by inactivation or deletion of PKR; antitumor agents |
| 03/27/2008 | US20080075727 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 03/27/2008 | US20080075726 Anti-IL-6 monoclonal antibodies and uses thereof |
| 03/27/2008 | US20080075714 Use of WNT inhibitors to augment therapeutic index of chemotherapy |
| 03/27/2008 | US20080075713 isomerase enzymes and ATP-binding cassette (ABC) transport proteins, used for controlling metabolism of triglycerides; diagnosis, prevention and treatment of metabolic disorders |
| 03/27/2008 | US20080075712 replacement for ligand of a heteromolecule-comprising a dimer, cytokine or interferon receptors; antibodies recognizing both an enzyme and a substrate, such as proteolytic enzymes and blood coagulation/fibrinolysis associated factors; prevention of bleeding and/or blood disorders |
| 03/27/2008 | US20080075705 induction of endogenous heat shock proteins in tumor cells, bysimple heat treatment as a method for augmenting antitumor vaccine potency |
| 03/27/2008 | US20080075659 Determining the percentage of monoclonal, chimerized, murine or humanized antibody greater than 90 percent using excess amount of CD66 antigen, and the percentage of immunoreactive antibody that binds specifically to CD66 |
| 03/27/2008 | DE112005003498T5 Herstellungsverfahren für Chinazolinderivate und Anwendung zur Herstellung zur Behandlung von Tumorerkrankungen A method for manufacturing and application for the production of quinazoline derivatives for the treatment of tumor diseases |
| 03/27/2008 | DE102006045097A1 Verwendungen von Cripowellinen und deren Derivate zur Behandlung von Tumorerkrankungen Uses of Cripowellinen and derivatives thereof for the treatment of tumor diseases |
| 03/27/2008 | CA2665816A1 Antigen specific multi epitope vaccines |
| 03/27/2008 | CA2665090A1 Methods for treating mica-related disorders |
| 03/27/2008 | CA2663994A1 Anti-cancer antibodies against lewisb and lewis antigens |
| 03/27/2008 | CA2663791A1 Pyrazolo (1, 5-a) (1, 3, 5) triazine and pyrazolo (1, 5-a) pyrimidine derivatives useful as protein kinase inhibitors |
| 03/27/2008 | CA2663599A1 Method for treating cancer harboring egfr mutations |
| 03/27/2008 | CA2663528A1 Heterocyclic inhibitors of c-met and uses thereof |
| 03/27/2008 | CA2663323A1 Formulations for therapeutic administration of thyroid stimulating hormone (tsh) |
| 03/27/2008 | CA2663242A1 Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors |
| 03/27/2008 | CA2663057A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 03/27/2008 | CA2662977A1 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors |